A citation-based method for searching scientific literature


List of co-cited articles
44 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.
J G Emery, P McDonnell, M B Burke, K C Deen, S Lyn, C Silverman, E Dul, E R Appelbaum, C Eichman, R DiPrinzio,[...]. J Biol Chem 1998
942
17

Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival.
Kian Behbakht, Lubna Qamar, Carrie S Aldridge, Ricardo D Coletta, Susan A Davidson, Andrew Thorburn, Heide L Ford. Cancer Res 2007
129
17

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.
H Walczak, R E Miller, K Ariail, B Gliniak, T S Griffith, M Kubin, W Chin, J Jones, A Woodward, T Le,[...]. Nat Med 1999
11


Sine Oculis Homeobox Homolog 1 Regulates Mitochondrial Apoptosis Pathway Via Caspase-7 In Gastric Cancer Cells.
Peizhun Du, Jing Zhao, Jing Wang, Yongchao Liu, Hong Ren, Rajan Patel, Cheng'en Hu, Wenhong Zhang, Guangjian Huang. J Cancer 2017
15
13

Chalcones enhance TRAIL-induced apoptosis in prostate cancer cells.
Ewelina Szliszka, Zenon P Czuba, Bogdan Mazur, Lukasz Sedek, Andrzej Paradysz, Wojciech Krol. Int J Mol Sci 2009
77
11

Six1 promotes proliferation of pancreatic cancer cells via upregulation of cyclin D1 expression.
Zhaoming Li, Tian Tian, Feng Lv, Yu Chang, Xinhua Wang, Lei Zhang, Xin Li, Ling Li, Wang Ma, Jingjing Wu,[...]. PLoS One 2013
68
11

The Six1 homeoprotein stimulates tumorigenesis by reactivation of cyclin A1.
Ricardo D Coletta, Kimberly Christensen, Kelly J Reichenberger, Justin Lamb, Damian Micomonaco, Lili Huang, Douglas M Wolf, Carsten Müller-Tidow, Todd R Golub, Kiyoshi Kawakami,[...]. Proc Natl Acad Sci U S A 2004
167
11

A protocol for isolation and culture of human umbilical vein endothelial cells.
Bruno Baudin, Arnaud Bruneel, Nelly Bosselut, Michel Vaubourdolle. Nat Protoc 2007
281
11

TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways.
Paola Secchiero, Arianna Gonelli, Edvige Carnevale, Daniela Milani, Assunta Pandolfi, Davide Zella, Giorgio Zauli. Circulation 2003
247
11

TRAIL induces apoptosis and inflammatory gene expression in human endothelial cells.
Jie Hui Li, Nancy C Kirkiles-Smith, Jennifer M McNiff, Jordan S Pober. J Immunol 2003
139
11

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family.
R M Pitti, S A Marsters, S Ruppert, C J Donahue, A Moore, A Ashkenazi. J Biol Chem 1996
11

The receptor for the cytotoxic ligand TRAIL.
G Pan, K O'Rourke, A M Chinnaiyan, R Gentz, R Ebner, J Ni, V M Dixit. Science 1997
11

Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer.
Roy S Herbst, S Gail Eckhardt, Razelle Kurzrock, Scot Ebbinghaus, Peter J O'Dwyer, Michael S Gordon, William Novotny, Meredith A Goldwasser, Tanyifor M Tohnya, Bert L Lum,[...]. J Clin Oncol 2010
322
11

TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB.
Harald Ehrhardt, Simone Fulda, Irene Schmid, John Hiscott, Klaus-Michael Debatin, Irmela Jeremias. Oncogene 2003
218
11

MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors.
S E Tran, T H Holmstrom, M Ahonen, V M Kahari, J E Eriksson. J Biol Chem 2001
274
11

Safety and antitumor activity of recombinant soluble Apo2 ligand.
A Ashkenazi, R C Pai, S Fong, S Leung, D A Lawrence, S A Marsters, C Blackie, L Chang, A E McMurtrey, A Hebert,[...]. J Clin Invest 1999
11

A set of NF-κB-regulated microRNAs induces acquired TRAIL resistance in lung cancer.
Young-Jun Jeon, Justin Middleton, Taewan Kim, Alessandro Laganà, Claudia Piovan, Paola Secchiero, Gerard J Nuovo, Ri Cui, Pooja Joshi, Giulia Romano,[...]. Proc Natl Acad Sci U S A 2015
53
11

TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL.
H Walczak, M A Degli-Esposti, R S Johnson, P J Smolak, J Y Waugh, N Boiani, M S Timour, M J Gerhart, K A Schooley, C A Smith,[...]. EMBO J 1997
961
11

TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB.
P Schneider, M Thome, K Burns, J L Bodmer, K Hofmann, T Kataoka, N Holler, J Tschopp. Immunity 1997
569
11

The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain.
M A Degli-Esposti, W C Dougall, P J Smolak, J Y Waugh, C A Smith, R G Goodwin. Immunity 1997
708
11

Characterization of two receptors for TRAIL.
P Schneider, J L Bodmer, M Thome, K Hofmann, N Holler, J Tschopp. FEBS Lett 1997
245
11

Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression.
Simone Fulda, Eric Meyer, Klaus-Michael Debatin. Oncogene 2002
306
11

TRAIL-R4 promotes tumor growth and resistance to apoptosis in cervical carcinoma HeLa cells through AKT.
Najoua Lalaoui, Aymeric Morlé, Delphine Mérino, Guillaume Jacquemin, Elisabetta Iessi, Alexandre Morizot, Sarah Shirley, Bruno Robert, Eric Solary, Carmen Garrido,[...]. PLoS One 2011
47
11

TRAIL mediates and sustains constitutive NF-κB activation in LGL leukemia.
Jun Yang, Francis R LeBlanc, Shubha A Dighe, Cait E Hamele, Thomas L Olson, David J Feith, Thomas P Loughran. Blood 2018
17
11

TRAIL receptor gene editing unveils TRAIL-R1 as a master player of apoptosis induced by TRAIL and ER stress.
Florent Dufour, Thibault Rattier, Andrei Alexandru Constantinescu, Luciana Zischler, Aymeric Morlé, Hazem Ben Mabrouk, Etienne Humblin, Guillaume Jacquemin, Eva Szegezdi, Fabien Delacote,[...]. Oncotarget 2017
48
11

Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy.
Agathe Dubuisson, Olivier Micheau. Antibodies (Basel) 2017
32
11

Prognostic significance of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor expression in patients with breast cancer.
Tom M Ganten, Jaromir Sykora, Ronald Koschny, Emanuela Batke, Sebastian Aulmann, Ulrich Mansmann, Wolfgang Stremmel, Hans-Peter Sinn, Henning Walczak. J Mol Med (Berl) 2009
59
11

Inhibition of death receptor signals by cellular FLIP.
M Irmler, M Thome, M Hahne, P Schneider, K Hofmann, V Steiner, J L Bodmer, M Schröter, K Burns, C Mattmann,[...]. Nature 1997
11


Identification of Mitoxantrone as a TRAIL-sensitizing agent for Glioblastoma Multiforme.
Filiz Senbabaoglu, Ahmet Cingoz, Ezgi Kaya, Selena Kazancioglu, Nathan A Lack, Ceyda Acilan, Tugba Bagci-Onder. Cancer Biol Ther 2016
19
11

Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells.
Jing Xu, Jun-Ying Zhou, Wei-Zen Wei, Gen Sheng Wu. PLoS One 2010
69
11

Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors.
J P Sheridan, S A Marsters, R M Pitti, A Gurney, M Skubatch, D Baldwin, L Ramakrishnan, C L Gray, K Baker, W I Wood,[...]. Science 1997
11

Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand.
Eugene Varfolomeev, Heather Maecker, Darcie Sharp, David Lawrence, Mark Renz, Domagoj Vucic, Avi Ashkenazi. J Biol Chem 2005
198
11

Death receptors as targets in cancer.
O Micheau, S Shirley, F Dufour. Br J Pharmacol 2013
124
11

Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2.
Delphine Mérino, Najoua Lalaoui, Alexandre Morizot, Pascal Schneider, Eric Solary, Olivier Micheau. Mol Cell Biol 2006
215
11

The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase.
Y Lin, A Devin, A Cook, M M Keane, M Kelliher, S Lipkowitz, Z G Liu. Mol Cell Biol 2000
195
11

Mechanisms of resistance to TRAIL-induced apoptosis in cancer.
Lidong Zhang, Bingliang Fang. Cancer Gene Ther 2005
512
11

ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancer.
Jie Yang, Chunxu Yang, Shimin Zhang, Zijie Mei, Mingjun Shi, Shaoxing Sun, Liu Shi, Zhihao Wang, Yacheng Wang, Zhenzhen Li,[...]. Cancer Biol Ther 2015
37
11

Developing TRAIL/TRAIL death receptor-based cancer therapies.
Xun Yuan, Ambikai Gajan, Qian Chu, Hua Xiong, Kongming Wu, Gen Sheng Wu. Cancer Metastasis Rev 2018
67
11

Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity.
K Ichikawa, W Liu, L Zhao, Z Wang, D Liu, T Ohtsuka, H Zhang, J D Mountz, W J Koopman, R P Kimberly,[...]. Nat Med 2001
467
11

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
11

Luteolin enhances TRAIL sensitivity in non-small cell lung cancer cells through increasing DR5 expression and Drp1-mediated mitochondrial fission.
Bin Wu, Jie Xiong, Ying Zhou, Yingtong Wu, Yun Song, Ning Wang, Lihua Chen, Jian Zhang. Arch Biochem Biophys 2020
4
50

Ginsenoside Rg3 suppresses FUT4 expression through inhibiting NF-κB/p65 signaling pathway to promote melanoma cell death.
Xiu Shan, Li Li Tian, Yu Mei Zhang, Xiao Qi Wang, Qiu Yan, Ji Wei Liu. Int J Oncol 2015
28
5




Paris Saponin I Sensitizes Gastric Cancer Cell Lines to Cisplatin via Cell Cycle Arrest and Apoptosis.
Shuichuan Song, Leiwen Du, Hao Jiang, Xinhai Zhu, Jinhui Li, Ji Xu. Med Sci Monit 2016
32
5

Cucurbitacin D induces cell cycle arrest and apoptosis by inhibiting STAT3 and NF-κB signaling in doxorubicin-resistant human breast carcinoma (MCF7/ADR) cells.
Jin Mo Ku, Soon Re Kim, Se Hyang Hong, Han-Seok Choi, Hye Sook Seo, Yong Cheol Shin, Seong-Gyu Ko. Mol Cell Biochem 2015
35
5


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.